scholarly journals CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer

2017 ◽  
Vol 11 (1) ◽  
pp. 89-91 ◽  
Author(s):  
Cameron M. Armstrong ◽  
Allen C. Gao
2015 ◽  
Vol 11 (01) ◽  
pp. 58
Author(s):  
Hema Vankayala ◽  
Ulka Vaishampayan ◽  
◽  

The face of metastatic prostate cancer (PC) has been remarkably reshaped with the current advances in its management. Kudos to the cuttingedge research that has pinpointed new targets and agents. The main stumbling block in this disease is progression on androgen deprivation therapy (ADT) and the development of castrate resistance. Despite this phenomenon, the majority of patients with PC continue to rely on androgen receptors (ARs) for disease growth and progression. Several of these newer agents directly or indirectly target ARs. Many drugs have earned US Food and Drug Administration (FDA) approval in the past decade by showing survival benefit, which is the gold standard endpoint in all the pivotal PC trials. An array of new targets and agents are being explored currently. The future of metastatic castration-resistant prostate cancer (mCRPC) appears exciting with the expanding armamentarium; however, the challenges of affordability and sequencing of the agents remain.


2021 ◽  
Vol 11 ◽  
Author(s):  
Fan Yang ◽  
Chong Yuan ◽  
Dan Wu ◽  
Jing Zhang ◽  
Xingchun Zhou

Castration-resistant prostate cancer (CRPC) is the lethal form of prostate cancer (PCa), and the underlying molecular mechanism has not been fully elucidated. Inositol requiring enzyme 1 alpha (IRE1α), a key regulator of unfolded protein response (UPR), is intimately associated with PCa progression. However, whether IRE1α is implicated in CRPC development remains unknown. Here, we showed that IRE1α expression was significantly increased in CRPC tissues and high-grade PCa tissues. Overexpression of IRE1α promoted PCa cell proliferation under the androgen deficiency condition in vitro and in vivo. Mechanistically, increased IRE1α expression induced IL-6 secretion via the IRE1α/XBP-1s signal pathway. IRE1α-induced IL-6 activated androgen receptor (AR), and the activation of AR by IL-6, in turn, promoted IRE1α expression. IRE1α formed a positive feedback loop with IL-6 and AR to promote prostate cancer cell proliferation under the androgen-deficient condition. In clinical PCa samples, high IRE1α expression correlated with elevated IL-6 and increased PSA expression. Our findings demonstrated a novel mechanism of CRPC progression and suggest targeting IRE1α may be a potential target for the prevention and treatment of CRPC.


2016 ◽  
Vol 77 (2) ◽  
pp. 412-422 ◽  
Author(s):  
Ka-wing Fong ◽  
Jonathan C. Zhao ◽  
Jung Kim ◽  
Shangze Li ◽  
Yeqing A. Yang ◽  
...  

2019 ◽  
Author(s):  
Mitchell G Lawrence ◽  
Laura H Porter ◽  
Daisuke Obinata ◽  
Shahneen Sandhu ◽  
Luke A Selth ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document